Clinical medicine profile
Mitomycin
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitive or idiosyncratic reaction to the drug
- those with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes
Precautions
- It must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents due to its low therapeutic index
- increased incidence of infections.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
IV 20mg/m2 as Single repeated every 6-8 wks. Consult specialist literature for further information.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Adenocarcinoma of the stomach and pancreas
- bladder cancer. [In combination with other agents] Clinical selection for Mitomycin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Bone marrow toxicity [most common and most serious adverse effect] manifested by thrombocytopenia, leukopenia and anaemia
- cellulitis at the injection site
- stomatitis
- alopecia
- necrosis and consequent sloughing of tissue in case extravasation
- pulmonary toxicity
- haemolytic ureamic syndrome
- anorexia
- nausea and vomiting.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
Its activity is similar to that of the alkylating agents i.
Read complete mechanism
Its activity is similar to that of the alkylating agents i.e. causing cross-linking of DNA hence interfering with DNA replication and transcription of RNA. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Hypersensitive or idiosyncratic reaction to the drug; those with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Consult specialist literature for further infor- | Afya Index product / manufacturer unverified | tabs 10mg 1's | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.